AmMax Bio Announces First Patient Dosed in Phase 2a Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease

Quick Summary:

AMB-066 is a potential first-in-class treatment for CRC MRD ~20,000 patients diagnosed annually in U.S.; no currently approved therapies     REDWOOD CITY, Calif., Jan.27, 2025 (GLOBE NEWSWIRE) -- AmMax Bio, Inc.("AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced the dosing of the first patient in its Phase 2a study (NCT06617858) evaluating AMB-066 for the treatment of patients with colorectal cancer minimal residual disease (CRC MRD).

The antibody has been tested in approximately 200 patients and healthy volunteers across six clinical trials for other indications and has been found to be generally safe and well tolerated.About AmMax Bio Inc.​AmMax, founded by Larry Hsu, Ph.D., in 2020, is a clinical-stage biotechnology company focused on the development of innovative therapeutics for cancer patients.

We look forward to sharing further updates as the study progresses.” CRC MRD is diagnosed when a patient without radiographic evidence of tumor tests positive with circulating tumor DNA.In the U.S., an estimated 20,000 patients annually are diagnosed with CRC MRD following definitive therapy, which includes curative intent surgery with or without perioperative chemotherapy.

Read Quick SummarySave Time

or

Article Details

Author / Journalist: AmMax Bio, Inc.

Category: Technology

Markets: China

Topics: Diagnosed Cancer Ammax Oncology Clinical Treatment Patient Patients Study Development Amb-066

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-27 @ 13:00:00 (4 days ago)

News Timezone: GMT +8:00

News Source URL: globenewswire.com

Language: English

Article Length: 448 words

Reading Time: 3 minutes read

Sentences: 12 lines

Sentence Length: 38 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © GlobeNewswire

News ID: 25502196

View Article Analysis

About GlobeNewswire

Main Topics: Technology

Official Website: globenewswire.com

Update Frequency: 44 posts per day

Year Established: 1998

Headquarters: China

News Last Updated: 9 hours ago

Coverage Areas: China

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #116

Publisher Details

Frequently Asked Questions